The answer to that question is NOBODY from big pharma - up to...

The answer to that question is NOBODY from big pharma - up to date thinks Imugene is a bargain at current market cap, not big pharma, or share market either.
I listened intently to the PH/LC podcast yesterday. Paul Hopper would have listeners believe that Imugene have simply been part of a blanket downturn in biotechs over the last two years, and that the price destruction is a sector issue rather than anything else. The reality is not actually that, rather several other Australian biotechs have thrived and substantially grown their market cap over that time ( in the absence of any commercial deals) , others have grown and achieved commercial success.
The nuclear winter PH describes is in his own backyard —HQ at IMU.
For a man who touts himself as knowing the top 50 biotech investors in the US, and the man who structures the capital for the business pre commercialisation, he has done a lousy job if you are seeing things from the eyes of the average retail holder. IE poor terms on deals, terrible investors who are kept secret and then short the absolute crap/sell out of their heavily discounted stock, ZERO commercial deals to date - in the case of Hervaxx after the completion of phase 2, and now what appears to be misguidance a couple of years back. This is on top of huge salary and performance rewards for executives, all the while the share price is crashing. I don’t know what the performance criteria is, it certainly can’t be market cap growth.
Have a good look in the mirror Paul Hopper, you might think you have done great things, but unfortunately the market and big pharma haven’t reacted in accordance in recent times. Take a bite of humble pie, admit some personal failures, even consider an apology? And then start the huge task of gaining some personal trust and credibility in the market place. Presently, there is a very poor regard for taking your word, a self inflicted state of play.
The science will prevail, I’m confident of that, we just didn’t have to have the pain that Hopper has brought upon us, it should have been a much smoother run.